



The Cleancatch® Midstream™ has achieved NHS tender, been adopted as an innovative urine collection solution all over the world and has now been approved as having *significant potential* by the NHS Centre For Evidence Based Purchasing.



NHS Report Demonstrates *Significant Potential* for Innovative Urology Device

The Cleancatch Midstream™ achieves NHS CEP approval...

The Cleancatch Midstream is a midstream urine sample collection device, designed and demonstrated to make urine sample collection automatic, patient and staff independent. It delivers a clinically proven, significantly superior and more accurate sample, which is collected more hygienically, cleanly, cheaply and more simply than anything currently available.

After over a year spent reviewing the device, the NHS Centre for Evidence based Purchasing (CEP), which reviews and offers advice on equipment and systems that would benefit the NHS, has just published a report which demonstrates the significant advantages and cost savings that the Cleancatch Midstream would bring to urology across the NHS. They have concluded that the device has *Significant Potential* for the NHS.

To date no CEP report in urology has reached "Recommended" status. *Significant Potential* is as high as has ever been achieved by any product.

The Cleancatch is a leap forward in technology and product design. While the equipment for the analysis of urine has improved dramatically in the last 100 years, the method of collection has barely changed. Even a modern analysis machine is rendered useless if the quality of the sample is poor and currently urine samples have a high inherent contamination rate – as high as 56% amongst GP's collected samples (Garcia et al, 2004). As demonstrated in large scale trials the Cleancatch can reduce this by up to 73% as well as reducing the number of retests that may be required.

It should be noted that the CEP report takes higher contamination rate data from Jackson et al 2005. However more recent and larger studies (Dryden et al, 2007) show that the product reduces

contamination rates to only 3-4%. Dryden et al is also community based which suggests a more accurate result.

This CEP report (#07004), despite choosing the most conservative data and using the most pessimistic evaluations still convincingly demonstrates that the device saves money, significantly reduces contamination rates, and increases staff and patient satisfaction.

The report, relevant clinical trials and supporting peer reviewed comments can be downloaded from:

www.whizproducts.co.uk/en/downloads.aspx

Clinical Trials Show:

Preferred by clinical staff	100%
Reduction in heavy mixed growth	60%
Reduction in spillage	41%
Reduces contamination rates to	4%

In an NHS system which is looking to save money...



The Cleancatch Midstream has been clinically proven to reduce contamination, but trials have also shown that it can reduce the cost of a single urine test to hospitals by over £30. With up to 40 million midstream urine samples taken annually in the UK, that represents a potential saving of up to **£1.2 billion** just from the uptake of the Cleancatch Midstream!

Notwithstanding the increase in patient comfort, the decrease in staff time required per test and the significant reduction in contamination rates, this product is clearly a undeniably important procurement decision for the NHS. The results speak for themselves.

ENDS